133 related articles for article (PubMed ID: 18432364)
41. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
Dingli D; Utz JP; Krowka MJ; Oberg AL; Tefferi A
Chest; 2001 Sep; 120(3):801-8. PubMed ID: 11555513
[TBL] [Abstract][Full Text] [Related]
42. Cytogenetic studies in chronic myeloproliferative disorders.
Carbonell F; Ganser A; Heimpel H
Acta Haematol; 1983; 69(3):145-51. PubMed ID: 6404096
[TBL] [Abstract][Full Text] [Related]
43. Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): Incidence in untreated myeloproliferative disorders.
Bendix-Hansen K
Scand J Haematol; 1986 Jan; 36(1):8-10. PubMed ID: 3006224
[TBL] [Abstract][Full Text] [Related]
44. Histomorphometric study of megakaryocytes in bone marrow in selected myeloproliferative and lymphoproliferative diseases.
Lemancewicz D; Dziecioł J; Kłoczko J; Litwiejko-Pietryńczak E; Bogusłowicz W
Folia Morphol (Warsz); 2003 Feb; 62(1):51-6. PubMed ID: 12769178
[TBL] [Abstract][Full Text] [Related]
45. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
Kaufman S; Brière J; Bernard J
Nouv Rev Fr Hematol (1978); 1978 Apr; 20(1):1-15. PubMed ID: 353725
[TBL] [Abstract][Full Text] [Related]
46. Development of JAK2V617F-positive polycythemia vera after chemotherapy-induced remission of primary central nervous system diffuse large B cell non-Hodgkin's lymphoma: a case report and review of the literature.
Elli EM; Belotti A; Cecchetti C; Realini S; Fedele M; Parma M; Pogliani EM
Acta Haematol; 2013; 130(3):142-5. PubMed ID: 23652352
[TBL] [Abstract][Full Text] [Related]
47. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
49. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
50. Acute non-lymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: cytogenetic studies.
Whang-Peng J; Knutsen T; O'Donnell JF; Brereton HD
Cancer; 1979 Nov; 44(5):1592-600. PubMed ID: 498031
[TBL] [Abstract][Full Text] [Related]
51. Secondary gout associated with chronic myeloproliferative disorders.
Yu T; Weinreb N; Wittman R; Wasserman LR
Semin Arthritis Rheum; 1976 Feb; 5(3):247-56. PubMed ID: 1062009
[No Abstract] [Full Text] [Related]
52. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies.
Weinberg RS; Worsley A; Gilbert HS; Cuttner J; Berk PD; Alter BP
Leuk Res; 1989; 13(4):331-8. PubMed ID: 2716348
[TBL] [Abstract][Full Text] [Related]
53. [Unusual case of chronic myeloproliferative syndrome].
Tosato F; Fossaluzza V
Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
[TBL] [Abstract][Full Text] [Related]
54. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
55. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.
Masarova L; Newberry KJ; Pierce SA; Estrov Z; Cortes JE; Kantarjian HM; Verstovsek S
Leuk Res; 2015 Aug; 39(8):822-7. PubMed ID: 26012362
[TBL] [Abstract][Full Text] [Related]
56. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
[TBL] [Abstract][Full Text] [Related]
57. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
58. Adhesion molecules in B-chronic lymphoproliferative disorders.
Angelopoulou MK; Kontopidou FN; Pangalis GA
Semin Hematol; 1999 Apr; 36(2):178-97. PubMed ID: 10319387
[TBL] [Abstract][Full Text] [Related]
59. Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders.
Munzert G; Kreitmeier S; Bergmann L
Leuk Lymphoma; 2000 Jul; 38(3-4):395-400. PubMed ID: 10830747
[TBL] [Abstract][Full Text] [Related]
60. [Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry].
Hu Y; Chen Y; Wang LH; Chen X; Fang F; Liu SQ; Wu XQ; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):349-56. PubMed ID: 24763004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
